Twist Bioscience 8-K

PositiveEarningsGuidance raised

DNA Synthesis and NGS growth support raised FY2026 revenue guidance; Q4 adjusted EBITDA breakeven target reaffirmed.

Filed 2026-02-02 07:20 ET

Summary

Q1 FY2026 results with raised FY2026 revenue guidance and Q2 guidance. Revenue rose 17% Y/Y, marking Twist Bioscience’s 12th consecutive quarter of sequential growth; the company raised its FY2026 revenue range and reiterated adjusted EBITDA breakeven in Q4 FY2026. Revenue growth spanned both segments, while NGS Applications growth was 18% excluding one large customer transitioning an assay from research to commercial.

Key Figures

Metric Q1 FY2026 Q1 FY2025 Y/Y
Revenue $103.7M $88.7M 17%
Loss from operations $(32.9)M $(34.6)M n/m
Net loss $(30.5)M $(31.6)M n/m
Diluted EPS $(0.50) $(0.53) n/m
Adjusted EBITDA, non-GAAP $(13.4)M $(16.3)M n/m
Gross margin 52.0% 48.3% +370 bp
  • DNA Synthesis and Protein Solutions revenue increased 27% to $51.1M; NGS Applications revenue increased 8% to $52.6M, or 18% excluding the large customer transition.
  • Cash, cash equivalents and short-term investments totaled ≈$198M at 12/31/2025.

Guidance

Metric Period Guidance Prior Direction
Revenue FY2026 $435M-$440M; 16% growth at midpoint $425M-$435M Raised
Gross margin FY2026 Above 52% — —
Revenue Q2 FY2026 ≈$107M-$108M; ≈16% Y/Y growth at midpoint — —
Adjusted EBITDA, non-GAAP Q4 FY2026 Breakeven — Reaffirmed

Q2 sequential growth is expected to be driven by key NGS accounts; the FY revenue increase versus prior guidance is expected to be generally balanced across DNA Synthesis and Protein Solutions and NGS.

Investor Takeaways

  • Compare Q2 revenue with the ≈$107M-$108M range and track progress toward the raised FY2026 revenue and gross margin outlook.
  • Q4 FY2026 adjusted EBITDA breakeven is the stated profitability milestone to watch.

The summary is written by an AI model reading the filing.

Model 005 · prompt 01d34d48e3

Feedback